このエントリーをはてなブックマークに追加
ID 48564
JaLCDOI
フルテキストURL
著者
Okada, Toshiaki Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine
Takigawa, Nagio Department of General Internal Medicine 4, Kawasaki Hospital, Kawasaki Medical School
Kishino, Daizo Department of Medicine, Yamaguchi-Ube Medical Center
Katayama, Hideki Department of Medicine, Yamaguchi-Ube Medical Center
Kuyama, Shouichi Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine
Sato, Ken Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine
Mimoto, Junko Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine
Ueoka, Hiroshi Department of Medicine, Yamaguchi-Ube Medical Center
Tanimoto, Mitsune Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine Kaken ID publons researchmap
Kiura, Katsuyuki Department of Respiratory Medicine, Okayama University Hospital ORCID Kaken ID publons researchmap
抄録
Cisplatin is used to treat lung cancer;however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated the effect of a COX-2 inhibitor, celecoxib, on cisplatin-induced lung tumors. One hundred twenty 4-week-old A/J mice were divided into 6 groups:group 1, no treatment;group 2, low-dose celecoxib (150mg/kg);group 3, high-dose celecoxib (1,500mg/kg);group 4, cisplatin alone;group 5, cisplatin plus low-dose celecoxib;and group 6, cisplatin plus high-dose celecoxib. Mice in groups 4-6 were administered cisplatin (1.62mg/kg, i.p.) once a week for 10 weeks between 7 and 16 weeks of age. All mice were sacrificed at week 30. Tumor incidence was 15.8% in group 1, 25% in group 2, 26.3% in group 3, 60% in group 4, 50% in group 5, and 50% in group 6. Tumor multiplicity was 0.2, 0.3, 0.3, 1.3, 1.0, and 0.6 in groups 1-6, respectively. Tumor multiplicity in the cisplatin-treated mice was reduced by celecoxib treatment in a dose-dependent manner (p<0.05, group 4 vs. group 6). Celecoxib significantly reduced COX-2 expression in cisplatin-induced tumors (p<0.01, group 4 vs. group 6).
キーワード
cisplatin
non-small cell lung cancer
celecoxib
cyclooxygenase-2
chemoprevention
Amo Type
Original Article
発行日
2012-06
出版物タイトル
Acta Medica Okayama
66巻
3号
出版者
Okayama University Medical School
開始ページ
245
終了ページ
251
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
著作権者
CopyrightⒸ 2012 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Science KeyUT